Literature DB >> 3386693

Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma.

M W Duncan1, P Compton, L Lazarus, G A Smythe.   

Abstract

We compared the value of plasma samples with that of 24-hour urine samples in identifying patients with pheochromocytoma among those with hypertension. We employed specific gas chromatographic-mass spectrometric analysis of both urine and plasma for simultaneous assay of norepinephrine and its neuronal metabolite 3,4-dihydroxyphenylglycol (DHPG). The study population consisted of 1086 patients with hypertension, among them 25 patients with proved pheochromocytoma. Reference ranges for free norepinephrine and DHPG in plasma and urine were established. Measurement of free norepinephrine in 24-hour urine samples provided the best index of a pheochromocytoma. This technique had 100 percent sensitivity and 98 percent specificity among 1192 urine samples, as compared with 82 percent sensitivity and 95 percent specificity among 358 plasma samples. Simultaneous measurement of norepinephrine and DHPG in urine further improved specificity (to 99 percent), but the use of the ratio of norepinephrine to DHPG reduced sensitivity (to 95 percent), since some patients with pheochromocytoma secrete large amounts of DHPG. We therefore recommend measurement of 24-hour urinary levels of free norepinephrine for the diagnosis of pheochromocytoma and suggest that simultaneous analysis for DHPG may sometimes prove useful in reducing the rate of false positive results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386693     DOI: 10.1056/NEJM198807213190303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

Review 1.  Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.

Authors:  G Eisenhofer; T T Huynh; M Hiroi; K Pacak
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Pheochromocytoma.

Authors:  P E Cryer
Journal:  West J Med       Date:  1992-04

3.  Paroxystic hypertension in a long-term hemodialyzed patient. Successful adrenalectomy for a dopamine-producing pheochromocytoma.

Authors:  A Ferrante; R Bellantone; A Barbarino; S Corsello; C A Rota; R Ranieri; L Sollazzi; M Sciarra; F Meo; G Luciani
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

4.  Detecting pheochromocytoma: defining the most sensitive test.

Authors:  Ulrich Guller; Joe Turek; Steve Eubanks; Elizabeth R Delong; Daniel Oertli; Jerome M Feldman
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 5.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

6.  Phaeochromocytomas and somatostatin production.

Authors:  C Weinkove
Journal:  BMJ       Date:  1989-06-17

Review 7.  Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines.

Authors:  Graeme Eisenhofer; Jacques W M Lenders; Karel Pacak
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

8.  34-year-old woman with hypotension, respiratory failure, fever, and an abdominal mass.

Authors:  P C Lee; C D Gocke; E D Harris; H E Pillsbury; C J Bergin; K L Vosti; K L Melmon; C Clinkingbeard
Journal:  West J Med       Date:  1993-05

Review 9.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

10.  Maternal intravaginal prostaglandin E2 gel before elective caesarean section at term to induce catecholamine surge in cord blood: randomised, placebo controlled study.

Authors:  M Singh; S Patole; A Rane; D Naidoo; P Buettner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.